Eduardo A. Novais, Mauricio Maia, Paulo Augusto de Arruda Mello Filho, João Rafael de Oliveira Dias, José Maurício B. B. Garcia, Gabriel C. de Andrade, Ricardo N. Louzada, Marcos Ávila, André Maia, J. Fernando Arevalo, Lihteh Wu, Maria Berrocal, Emmerson Badaró, and Michel Farah
Purpose. To evaluate the best-corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of dexamethasone implants needed to treat cystoid macular edema (CME) from various etiologies over 12 months in vitrectomized and nonvitrectomized eyes. Methods. This multicenter retrospective cohort study included 112 patients with CME secondary to retinal diseases treated pro re nata (PRN) with a 0.7 mg intravitreal dexamethasone implant for 12 months. The BCVA, CRT, adverse events, safety data, and number of implants were recorded. Results. Vitrectomized and nonvitrectomized eyes received means of three implants and one implant, respectively, over 12 months (P